பப்லொ பறவைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from பப்லொ பறவைகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In பப்லொ பறவைகள் Today - Breaking & Trending Today
PharmaMar’s cancer drug has ‘potent preclinical efficacy’ against COVID-19 Early study results published in peer-reviewed journal Science Spanish pharma company PharmaMar’s cancer drug Aplidin (plitidepsin) has demonstrated ‘potent preclinical efficacy’ against SARS-CoV-2, the virus which causes COVID-19. A research article, published in the peer-reviewed journal Science, detailed the findings from an in vitro and in vivo study which evaluated the drug’s ability to inhibit the protein eEF1A as a target for the treatment of COVID-19. Aplidin inhibits the eEF1A protein, which is associated with the SARS-CoV-2 virus, and is approved in Australia as a multiple myeloma treatment. ....
The U.S. new cases 7-day rolling average are 17.3 % LOWER than the 7-day rolling average one week ago. U.S. hospitalizations due to COVID-19 are now 8.6 % LOWER than the rolling average one week ago. U.S. deaths due to coronavirus are now 11.8 % HIGHER than the rolling average one week ago. Today s posts include: U.S. Coronavirus New Cases are 146,640 U.S. Coronavirus hospitalizations are at an elevated 108,957 U.S. Coronavirus deaths are at an elevated 4,087 U.S. Coronavirus immunizations have been administered to 7.1 % of the population The 7-day rolling average rate of growth of the pandemic shows new cases worsened, hospitalizations improved, and deaths worsened ....
Science that confirmed potent preclinical efficacy of its drug Aplidin against Covid-19. A study carried out in vitro and in vivo by a team of scientists in New York, San Francisco and Paris showed Aplidin (plitidepsin) leads to a reduction of viral replication, resulting in a 99% reduction of viral loads in the lungs of animals, the Science paper reported, according to a PharmaMar statement. The drug, approved in Australia for the treatment of multiple myeloma, blocks a protein associated with the Covid-19 virus. Toxicity of the drug is well known and the doses used in Covid-19 trials are well tolerated in humans, the company said. ....